Intracranial Granulocytic Sarcoma After Chemotherapy for Pineal Germinoma and Testicular Cancer

Passarin, Maria Grazia; Vattemi, Emanuela; Musso, Anna Maria; Romito, Silvia; Moretto, Giuseppe; Ghimenton, Claudio; Iuzzolino, P.; Doglioni, Claudio; Pedersini, Rebecca

doi:10.1200/jco.2008.17.0787

Cited by 12 publications

(6 citation statements)

References 16 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38 The AVITA (BO17706) phase III study of patients with metastatic pancreatic cancer reported that the addition of bevacizumab to gemcitabine and erlotinib did not significantly prolong overall survival, although a significant improvement in progression-free survival was seen (Table 2). 39 A number of other trials are being conducted to examine bevacizumab in combination with other agents or treatment modalities for pancreatic cancer; however, this agent seems unlikely to confer sufficient benefit to justify its licensing for this condition.…”

Section: Targeted Therapies In Clinical Trialsmentioning

confidence: 99%

Pancreatic cancer: molecular pathogenesis and new therapeutic targets

Wong

Lemoine

2009

Nat Rev Gastroenterol Hepatol

187

158

View full text Add to dashboard Cite

Patients with pancreatic cancer normally present with advanced disease that is lethal and notoriously difficult to treat. Survival has not improved dramatically despite routine use of chemotherapy and radiotherapy; this situation signifies an urgent need for novel therapeutic approaches. Over the past decade, a large number of studies have been published that aimed to target the molecular abnormalities implicated in pancreatic tumor growth, invasion, metastasis, angiogenesis and resistance to apoptosis. This research is of particular importance, as data suggest that a large number of genetic alterations affect only a few major signaling pathways and processes involved in pancreatic tumorigenesis. Although laboratory results of targeted therapies have been impressive, until now only erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has demonstrated modest survival benefit in combination with gemcitabine in a phase III clinical trial. Whilst the failures of targeted therapies in the clinical setting are discouraging, lessons have been learnt and new therapeutic targets that hold promise for the future management of the disease are continuously emerging. This Review describes some of the important developments and targeted agents for pancreatic cancer that have been tested in clinical trials.

show abstract

Section: Targeted Therapies In Clinical Trialsmentioning

confidence: 99%

Pancreatic cancer: molecular pathogenesis and new therapeutic targets

Wong

Lemoine

2009

Nat Rev Gastroenterol Hepatol

187

158

View full text Add to dashboard Cite

show abstract

“…Literature search only shows eight similar reports (isolated intracranial MS) from January 2000 to June 2019 (Table 1). [10][11][12][13][14][15][16][17] MS is generally diagnosed by a comprehensive analysis of clinical and imaging features, tissue biopsy, immunohistochemistry and molecular analyses. MS nodules or masses, which are characterized using radiologic evaluation, are denser than the brain parenchyma or are equivalent to muscles on CT scans.…”

Section: Discussionmentioning

confidence: 99%

<p>Isolated Intracranial Myeloid Sarcoma Mimicking Malignant Lymphoma: A Diagnostic Challenge and Literature Reviews</p>

Xu¹,

Zhang²,

Nong³

et al. 2020

OTT

View full text Add to dashboard Cite

Isolated intracranial myeloid sarcoma (MS) is an unusual variant tumor with few cases reported so far in the medical literature. A 29-year-old woman was admitted to our hospital presenting progressive visual loss in the right eye and weight loss (20 kg) without a previous history of hematological disease (HD). Radiologic evaluation showed the evidence of intracranial mass. Histologically, the resected tumor was composed of a uniform population of primitive cells and primarily misdiagnosed as a T-cell non-Hodgkin's lymphoma (NHL). Chemotherapy with cyclophosphamide, doxorubicin, vinblastine, and prednisone (CHOP) was ineffective. A biopsy and histopathological evaluation were repeated, and immunohistochemical staining revealed the positivity of immature cells to an extensive panel of myeloid markers. These findings were consistent with a diagnosis of MS and bone marrow infiltration. Literature reviews of previous cases were also undertaken.

show abstract

“…CNS involvement by MS occurs in the form of leptomeningeal or skull bone‐based extra‐axial masses and parenchymal infiltration has been reported in only a minority of cases . CNS localizations of MS display radiological imaging that could easily mimic a primitive intracranial tumor, mainly a meningioma, and differentiation from other entities could be difficult .…”

Section: Discussionmentioning

confidence: 99%

“…The most common localization of MS is the subperiosteal space of the skull, paranasal sinuses, sternum, ribs, vertebrae and pelvis; the lymph nodes and skin are also common sites . CNS involvement by MS is rare, and commonly occurs as extra‐axial masses, leptomeningeal or skull‐bone based; CNS parenchymal localization exclusively is rare, more frequently subsequent to a primitive meningeal involvement …”

Section: Introductionmentioning

confidence: 99%

Myeloid sarcoma with megakaryoblastic differentiation mimicking a sellar tumor

et al. 2013

View full text Add to dashboard Cite

Myeloid sarcoma (MS) is a localized extra-medullary tumor mass of immature myeloid cells, arising de novo or related to acute myeloid leukemia, of which it can be a forerunner, a coinciding or late event. Less commonly, MS represents an acute blastic transformation of myelodysplastic syndromes or myeloproliferative neoplasms. This rare condition commonly consists of a proliferation of more or less immature cells with a myeloid immunophenotype, very exceptional cases showing a megakaryoblastic or erythroid differentiation. The most common localization of MS is the skin, lymph node, soft tissues and bones, but CNS involvement is exceedingly rare, with no cases reported in the sellar region. We report a 54-year-old man, affected by myeloproliferative neoplasm, JAK2 V617F-positive of 13 years duration, who acutely presented with a third cranial nerve palsy; neuroradiology documented a space-occupying lesion at the level of the sellar, upper clival and right parasellar regions, that was sub-totally removed with a trans-sphenoidal approach. The histological examination documented a proliferation of large, blastic cells, frequently multinucleated; a diagnosis of MS with megakaryoblastic differentiation, arising in a background of chronic idiopathic myelofibrosis, was suggested by immunohistochemistry, owing to CD42b, CD45, CD61 and LAT (linker for activation of T cells) positivity. In addition, homozygous JAK2 V617F mutation was detected from the myeloid sarcoma specimen. A few weeks after surgery, an acute blastic leukemic transformation occurred and, despite chemotherapy, the patient died 2 months after surgery. To the best of our knowledge, this is the first MS case with megakaryoblastic differentiation arising within the CNS.

show abstract

Intracranial Granulocytic Sarcoma After Chemotherapy for Pineal Germinoma and Testicular Cancer

Cited by 12 publications

References 16 publications

Pancreatic cancer: molecular pathogenesis and new therapeutic targets

Pancreatic cancer: molecular pathogenesis and new therapeutic targets

<p>Isolated Intracranial Myeloid Sarcoma Mimicking Malignant Lymphoma: A Diagnostic Challenge and Literature Reviews</p>

Myeloid sarcoma with megakaryoblastic differentiation mimicking a sellar tumor

Contact Info

Product

Resources

About